Publications by authors named "Sara A Yones"

Transcriptomic analyses are commonly used to identify differentially expressed genes between patients and controls, or within individuals across disease courses. These methods, whilst effective, cannot encompass the combinatorial effects of genes driving disease. We applied rule-based machine learning (RBML) models and rule networks (RN) to an existing paediatric Systemic Lupus Erythematosus (SLE) blood expression dataset, with the goal of developing gene networks to separate low and high disease activity (DA1 and DA3).

View Article and Find Full Text PDF

Gliomas develop and grow in the brain and central nervous system. Examining glioma grading processes is valuable for improving therapeutic challenges. One of the most extensive repositories storing transcriptomics data for gliomas is The Cancer Genome Atlas (TCGA).

View Article and Find Full Text PDF

Small-compound databases contain a large amount of information for metabolites and metabolic pathways. However, the plethora of such databases and the redundancy of their information lead to major issues with analysis and standardization. A lack of preventive establishment of means of data access at the infant stages of a project might lead to mislabelled compounds, reduced statistical power, and large delays in delivery of results.

View Article and Find Full Text PDF

Numerous studies have been performed over the last decade to exploit the complexity of genomic and transcriptomic lesions driving the initiation of acute myeloid leukemia (AML). These studies have helped improve risk classification and treatment options. Detailed molecular characterization of longitudinal AML samples is sparse, however; meanwhile, relapse and therapy resistance represent the main challenges in AML care.

View Article and Find Full Text PDF

Normal karyotype acute myeloid leukemia (NK-AML) constitutes 20-25% of pediatric AML and detailed molecular analysis is essential to unravel the genetic background of this group. Using publicly available sequencing data from the TARGET-AML initiative, we investigated the mutational landscape of NK-AML in comparison with abnormal karyotype AML (AK-AML). In 164 (97.

View Article and Find Full Text PDF
Article Synopsis
  • Relapse is the main cause of death for patients with acute myeloid leukemia (AML), and understanding the mutations at both diagnosis and relapse can help improve treatment options and risk assessments.* -
  • Researchers conducted extensive genome analyses on 48 adult and 25 pediatric AML patients, discovering new mutations (notably in ARID1A and CSF1R) that could lead to potential new therapies, especially at relapse.* -
  • The study also highlighted significant differences between adult and pediatric relapsed AML mutational patterns, emphasizing the importance of understanding these unique alterations for better personalized treatment strategies.*
View Article and Find Full Text PDF

The tumor, node, metastasis (TNM) staging system has been regarded as one of the most widely used staging systems for solid cancer. The "T" is assigned a value according to the primary tumor size, whereas the "N" and "M" are dependent on the number of regional lymph nodes and the presence of distant metastasis, respectively. The current TNM model classifies stages into five crisp classes.

View Article and Find Full Text PDF